Designing safer glucocorticoid drugs

ScienceDaily (Dec. 1, 2010) ? Glucocorticoid drugs are used widely to treat numerous conditions, including rheumatoid arthritis, allergic reactions, asthma, and some forms of cancer, and transplant recipients. The beneficial effects of these drugs are their potent antiinflammatory and immunosuppressive properties. However, their long-term use is limited by severe side effects, including high blood levels of glucose, fatty liver, and type 2 diabetes.

A team of researchers, led by Carolyn Cummins, at the University of Toronto, Ontario, has now shown that the protein LXR-beta is required in mice for glucocorticoid drugs to elicit many of their negative side effects. Importantly, although mice lacking LXR-beta did not develop high levels of blood glucose or fatty liver when administered a glucocorticoid drug, they did show all the signs of immunosuppression.

The authors therefore suggest that glucocorticoid drugs designed to selectively target the glucocorticoid receptor and not LXR-beta should be safer than those currently in clinical use.

The research appears in the Journal of Clinical Investigation.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.

Story Source:

The above story is reprinted (with editorial adaptations by ScienceDaily staff) from materials provided by Journal of Clinical Investigation, via EurekAlert!, a service of AAAS.

Journal Reference:

Rucha Patel, Monika Patel, Ricky Tsai, Vicky Lin, Angie L. Bookout, Yuan Zhang, Lilia Magomedova, Tingting Li, Jessica F. Chan, Conrad Budd, David J. Mangelsdorf, Carolyn L. Cummins. LXRβ is required for glucocorticoid-induced hyperglycemia and hepatosteatosis in mice. Journal of Clinical Investigation, 2010; DOI: 10.1172/JCI41681

Note: If no author is given, the source is cited instead.

View the original article here